for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tandem Diabetes Care Inc

TNDM.OQ

Latest Trade

64.27USD

Change

0.00(0.00%)

Volume

215,666

Today's Range

62.74

 - 

64.35

52 Week Range

26.40

 - 

74.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
64.27
Open
63.18
Volume
215,666
3M AVG Volume
29.28
Today's High
64.35
Today's Low
62.74
52 Week High
74.80
52 Week Low
26.40
Shares Out (MIL)
59.09
Market Cap (MIL)
3,797.90
Forward P/E
-124.80
Dividend (Yield %)
--

Next Event

Tandem Diabetes Care Inc at Stifel Healthcare Conference

Latest Developments

More

Tandem Diabetes Care Announces Third Quarter 2019 Financial Results And Updated 2019 Financial Guidance

Tandem Diabetes Care Posts Q2 LOSS PER SHARE Of $0.03

Tandem Diabetes Care Reports Qtrly Loss Per Share $0.40

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc. is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim X2 Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). Its technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump's cartridge rather than relying on a syringe and plunger mechanism. It also features a software, which is a vivid color touch screen and a micro- universal serial bus (USB) connection that supports both a rechargeable battery and uploads to t:connect Diabetes Management Application (t:connect), its custom cloud-based data management application that provides display therapy management data from the pump and supported blood glucose meters.

Industry

Medical Equipment & Supplies

Contact Info

11075 Roselle St

+1.858.3666900

https://www.tandemdiabetes.com/

Executive Leadership

Kim D. Blickenstaff

Executive Chairman of the Board

John F. Sheridan

President, Chief Executive Officer, Director

Leigh A. Vosseller

Chief Financial Officer, Senior Vice President, Treasurer

Susan M. Morrison

Executive Vice President, Chief Administrative Officer

David B. Berger

Executive Vice President, General Counsel, Secretary

Key Stats

1.83 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.2K

2019(E)

0.4K
EPS (USD)

2016

-25.800

2017

-13.410

2018

-2.550

2019(E)

-0.515
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.51
Price To Book (MRQ)
22.72
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-15.04
Return on Equity (TTM)
-10.00

Latest News

Latest News

BRIEF-Tandem Diabetes Care Receives CE Mark for t:slim X2 Insulin Pump

* TANDEM DIABETES CARE-ANNOUNCED RECEIPT OF CE MARK APPROVAL FOR T:SLIM X2 INSULIN PUMP WITH DEXCOM G5® MOBILE CONTINUOUS GLUCOSE MONITORING INTEGRATION

BRIEF-Tandem Diabetes Care Files For Mixed Shelf Of Up To $100 Mln

* TANDEM DIABETES CARE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source : https://bit.ly/2JtPqwk Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Tandem Diabetes Care Reports Qtrly Net Loss Per Share, Basic And Diluted Of $1.82

* TANDEM DIABETES CARE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Tandem Diabetes Care Announces Insulin Pump Products Distribution Agreements In Australia And New Zealand

* TANDEM DIABETES CARE SAYS ANNOUNCES AGREEMENTS FOR DISTRIBUTION OF INSULIN PUMP PRODUCTS IN AUSTRALIA AND NEW ZEALAND Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care Q1 Sales $27 Mln Vs I/B/E/S View $25 Mln

* TANDEM DIABETES CARE ANNOUNCES PRELIMINARY FIRST QUARTER 2018 RESULTS

BRIEF-Tandem Diabetes Care And Movi SpA Announce Agreement For Distribution Of Insulin Pump Products In Italy

* TANDEM DIABETES CARE AND MOVI SPA ANNOUNCE AGREEMENT FOR DISTRIBUTION OF INSULIN PUMP PRODUCTS IN ITALY

BRIEF-Tandem Diabetes Care Q4 Sales $40.3 Million

* SALES FOR Q1 OF 2018 ARE ESTIMATED TO BE 18 PERCENT - 19 PERCENT OF ANNUAL SALES

BRIEF-Tandem Diabetes Care Applies For Health Canada Medical Device License

* TANDEM DIABETES CARE APPLIES FOR HEALTH CANADA MEDICAL DEVICE LICENSE

BRIEF-Tandem Diabetes Care Files For Offering Of 13.5 Mln Shares Of Co's Common Stock

* TANDEM DIABETES CARE FILES FOR OFFERING OF 13.5 MILLION SHARES OF CO'S COMMON STOCK, PAR VALUE $0.001 PER SHARE - SEC FILING Source text: (http://bit.ly/2nmA5Fh) Further company coverage:

BRIEF-Tandem Diabetes Care Sees Q4 2017 GAAP Sales Of About $39 Mln to $40 Mln

* TANDEM DIABETES CARE ANNOUNCES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 GUIDANCE

BRIEF-Tandem Diabetes Care Says May Offer Combination Of Stock Not Exceeding $10.7 Mln

* TANDEM DIABETES CARE SAYS MAY OFFER COMBINATION OF STOCK, PREFERRED STOCK, WARRANTS OR UNITS HAVING INITIAL OFFERING PRICE NOT EXCEEDING $10.7 MILLION Source text: (http://bit.ly/2oGBPwa) Further company coverage:

BRIEF-Tandem Diabetes Care reports Q3 sales of $27 million

* Tandem Diabetes Care reports third quarter 2017 financial results

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers

BRIEF-Empery Asset Management reports 5.63 pct passive stake in Tandem Diabetes Care

* Empery Asset Management Lp reports 5.63 pct passive stake in Tandem Diabetes Care Inc as of Oct 13 - SEC filing Source text: (http://bit.ly/2hSFBfg) Further company coverage:

BRIEF-Tandem Diabetes Care sees Q3 sales of about $26.5 mln to $27.5 mln

* Sees Q3 sales about $26.5 million to $27.5 million - sec filing

BRIEF-Tandem Diabetes Care announces proposed public offering of common stock

* Tandem Diabetes Care announces proposed underwritten public offering of common stock, Series A warrants and Series B warrants Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care‍ shareholders approv reverse stock split

* Tandem Diabetes Care Inc- shareholders subsequently approved reverse stock split at a ratio of 1-for-10 Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

BRIEF-Tandem Diabetes Care announces issuance of patent related to remote bolus feature for medical infusion pumps

* Tandem Diabetes Care announces issuance of patent related to remote bolus feature for medical infusion pumps Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care begins enrollment for 1st touchscreen insulin pump with PGLS

* Tandem Diabetes Care begins enrollment in pivotal trial for first touchscreen insulin pump with predictive low glucose suspend (PLGS)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up